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family unit (in terms of family commitment, confidence,
challenge, and control) as a potential factor influencing
outcomes of care for ill children. A potential consequence
of care giving is the loss of time or performance in other
aspects of the caregiver’s life (for instance work or aca-
demic productivity).
METHODS: We measured family hardiness and produc-
tivity using validated instruments that provide index
measures for each; family hardiness index (FHI) and
work productivity and activity index (WPAI) in 60 fami-
lies presenting to a pediatric neurology clinic. The FHI
score was used to stratify families into three groups: low
hardiness (FHI  40); medium hardiness (FHI  41–50),
and high hardiness (FHI  51–60). Participating families
were dichotomized into two groups based on WPAI: fam-
ilies whose caregiver reported a WPAI decrement, and
families whose caregiver reported no WPAI decrement.
Relative odds were calculated using chi-square test of as-
sociation (univariate) to determine the association of FHI
with WPAI. The odds of reporting a WPAI decrement
were calculated for each FHI strata compared with the
highest FHI stratum.
RESULTS: The relative odds, 95% CI (p  value) of re-
porting a WPAI decrement in the low (FHI 
 40) and
medium (FHI 41–50) strata compared to the high (FHI
51–60) stratum were 3.4, 0.3 to 35.0 (p  0.29) and 1.3,
0.3 to 5.4 (p  0.73), respectively.
CONCLUSION: Recognizing factors associated with dis-
ease burden may allow providers of epilepsy care to offer
families additional supportive services that may be associ-
ated with important indirect consequences of disease, such
as productivity. Although not significant, our results sug-
gest that family hardiness might be useful for this purpose,
however further validation studies are needed. The influ-
ence of seizure severity and therapy type on productivity
should also be determined using a multivariate approach.
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OBJECTIVES: This study is the first to compare adverse
reaction reports of rivastigmine and donepezil using real-
world data.
METHODS: This study uses the 2000 FDA Quarterly
Data from the Adverse Event Reporting System (AERS).
Total prescription and sales data for rivastigmine and
donepezil was utilized to determine the number of pa-
tients prescribed each drug. Adverse drug reaction mea-
surements as a proportion of users of each drug were
then obtained. Analyses tested proportional differences.
RESULTS: The most frequent common adverse reactions
were nausea and malaise for rivastigmine, and interac-
tions and convulsions for donepezil. Results show no sta-
tistically significant differences between rivastigmine and
donepezil in total rate of adverse drug reactions and rate
of serious adverse drug reactions. In contrast, the rate of
common adverse events found in donepezil was signifi-
cantly higher compared to its product labeling (p  .05).
The adverse event rate from drug interactions is signifi-
cantly higher for donepezil (p  .05).
CONCLUSIONS: As indicated from the FDA’s AERS,
similar rates of adverse events and serious adverse events
for rivastigmine and donepezil were found. Efficacy and
concomitant medication usage should be considerations
when selecting therapies for Alzheimer’s disease.
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OBJECTIVES: To assess the cost-effectiveness of high fre-
quency stimulation of the subthalamic nucleus (DBS-STN)
in patients with idiopathic Parkinson’s disease (PD).
METHODS: Sixteen PD patients were treated with DBS-
STN. Clinical evaluations were done at baseline and at 1,
3, 6 and 12 months following surgery by means of the
UPDRS. To evaluate the quality of life we included the
Sickness Impact Profile at baseline and at six months af-
ter surgery. Relevant economic data were taken from
medical records and costs were derived from different
German medical economic resources. Costs were deter-
mined from the perspective of the health-care provider.
RESULTS: Following DBS-STN UPDRS, subscores de-
creased as well as the sum score of UPDRS. Quality of
life improved considerably in PD patients treated with
DBS-STN. The physical dimension score (p  .009) as
well as the overall SIP score was different (p  .01) six
months after surgery compared to baseline values. Mean
costs of DM 40,020 per patient were spent during the 12-
month observation period for inpatient and outpatient
care. These expenses included the cost for the electronic
device for bilateral stimulation. Following DBS-STN,
medication was considerably reduced. Mean daily drug
costs at baseline were DM 46.7  21.8 and DM 18.3 
17.7 at 12 months following DBS-STN. Furthermore, we
used cost and UPDRS scores to estimate the incremental
cost-effectiveness of DBS-STN relative to baseline treat-
ment patterns. Treatment with DBS-STN had higher costs
but was more effective than baseline treatment. The in-
cremental CE ratio for DBS-STN was DM 1.800 for one
unit of decrease of the UPDRS.
CONCLUSIONS: DBS-STN is an effective treatment,
which considerably alleviates the severity and signs and
symptoms and improves the quality of life of patients
